Trials / Completed
CompletedNCT01315210
D-Ribose for Fatigue in Subjects With Fibromyalgia
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of D-Ribose in Subjects With Fibromyalgia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- RiboCor, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and to determine the efficacy of D-ribose for the amelioration of fatigue in subjects with fibromyalgia. This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center, multiple dose study of D-ribose versus placebo administered at doses of 5 g three times a day (TID) over a 12-week period to subjects who are experiencing fatigue associated with a diagnosis of fibromyalgia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | D-Ribose Powder | 5 g TID for 12 Weeks |
| DIETARY_SUPPLEMENT | Placebo Powder | 5 g TID for 12 Weeks |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2011-03-15
- Last updated
- 2013-09-18
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01315210. Inclusion in this directory is not an endorsement.